- Home
- STEM vs TCRX Comparison
STEM vs TCRX Comparison
Compare STEM & TCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | STEM | TCRX |
|---|---|---|
| Founded | 2009 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 75.3M | 75.7M |
| IPO Year | 2020 | 2021 |
Fundamental Metrics
Financial Performance| Metric | STEM | TCRX |
|---|---|---|
| Price | $10.73 | $1.25 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | ★ $13.33 | $7.00 |
| AVG Volume (30 Days) | 90.6K | ★ 1.3M |
| Earning Date | 05-06-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 12.28 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $156,266,000.00 | $10,325,000.00 |
| Revenue This Year | $2.77 | N/A |
| Revenue Next Year | $14.65 | $19.81 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 8.08 | ★ 266.65 |
| 52 Week Low | $0.35 | $0.88 |
| 52 Week High | $32.23 | $2.57 |
Technical Indicators
Market Signals| Indicator | STEM | TCRX |
|---|---|---|
| Relative Strength Index (RSI) | 51.24 | 54.47 |
| Support Level | $10.04 | $0.93 |
| Resistance Level | $10.99 | $1.97 |
| Average True Range (ATR) | 0.85 | 0.11 |
| MACD | -0.03 | -0.00 |
| Stochastic Oscillator | 30.84 | 33.33 |
Price Performance
Historical ComparisonAbout STEM Stem Inc.
Stem Inc is a provider of energy storage systems. The company bundles third-party hardware with its proprietary Athena software to provide customers a turnkey solution. Stem sells its solutions to commercial and industrial customers as well as independent power producers and renewable developers. Its solutions help customers maximize renewable energy generation and help build a cleaner and more resilient grid. The Company operates as one operating segment that is focused exclusively on technology services that transform the way energy is distributed and consumed.
About TCRX TScan Therapeutics Inc.
TScan Therapeutics Inc is a fully integrated clinical-stage biotechnology company focused on developing a robust pipeline of T cell receptor (TCR)-engineered T cell, or TCR-T, therapies for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.